The key results message was “more of the same”, including: i) market-beating core NAV growth (known given previous disclosures); ii) strong EBITDA growth in underlying companies; iii) good cash generation;
2019 results were announced on 12 February. 90% of Primary Health Properties PLC (LON:PHP) income is backed by the UK or RoI governments. Occupancy consistently exceeds 99%. We are confident
Diurnal Group PLC (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently
Burford Capital Limited (LON:BUR) recently released its first-ever trading statement, covering cash activity in 2019. Group-wide commitments set a new record of $1.57bn, a 24% increase. Overall deployments were almost
Initiation of our coverage was 16 March 2016 at 101.5p. In February 2018, the price was 215p and it stayed north of £2 for another year. In fiscal 2019, though,
City of London Investment Group (LON:CLIG) has announced its interim results for 1H’20. Several of the key figures were announced in the January trading statement, so the main interest is
Arix Bioscience (Arix) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage biotech
Neodecortech (NDT) performed well in 2019, in our view, against a difficult economic backdrop with trading picking up in 2H after a tricky 1H. The immediate outlook for 2020 remains
The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the
The recent trading update revealed sustained challenging markets. Chamberlin, however, is still on track strategically, and the group continues to develop its product offering most favourably. The group has been
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
